The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis

Experimental Neurology

Volumn 247, Issue , 2013, Pages 80-90

  Kraft, Peter ^a   Schwarz, Tobias ^a   Göb, Eva ^a   Heydenreich, Nadine ^a   Brede, Marc ^a   Meuth, Sven G ^b   Kleinschnitz, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Apoptosis; Blood brain barrier; Cytokines; Edema; Inflammation; Middle cerebral artery occlusion; Phosphodiesterase inhibitor; Rolipram; Stroke; Thrombosis

Indexed keywords

CLAUDIN 5; INTERLEUKIN 1BETA; OCCLUDIN; ROLIPRAM; TIGHT JUNCTION PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATTENUATION; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN NERVE CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; ENCEPHALITIS; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NEUTROPHIL; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; TREATMENT DURATION;

APOPTOSIS; BLOOD-BRAIN-BARRIER; CYTOKINES; EDEMA; INFLAMMATION; MIDDLE CEREBRAL ARTERY OCCLUSION; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; STROKE; THROMBOSIS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN EDEMA; BRAIN INJURIES; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALITIS; ENDOTHELIN-1; HEMODYNAMICS; INFARCTION, MIDDLE CEREBRAL ARTERY; LASER-DOPPLER FLOWMETRY; MALE; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; OCCLUDIN; PHOSPHODIESTERASE 4 INHIBITORS; ROLIPRAM; STROKE; THROMBOSIS;

EID: 84877136156     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.03.026     Document Type: Article

References (72)

1. Albert-Weißenberger C., Sirén A.L., et al. Ischemic stroke and traumatic brain injury: the role of the kallikrein-kinin system. Prog. Neurobiol. 2013, 101-102:65-82.
2. Allan S.M., Tyrrell P.J., et al. Interleukin-1 and neuronal injury. Nat. Rev. Immunol. 2005, 5:629-640.
3. Araki T., Kanai Y., et al. Sequential alteration of [3H]rolipram binding in gerbil brain after transient cerebral ischemia. Brain Res. Bull. 1993, 31:85-89.
4. Arumugam T.V., Salter J.W., et al. Contributions of LFA-1 and Mac-1 to brain injury and microvascular dysfunction induced by transient middle cerebral artery occlusion. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H2555-H2560.
5. Atkins C.M., Oliva A.A., et al. Modulation of the cAMP signaling pathway after traumatic brain injury. Exp. Neurol. 2007, 208:145-158.
6. Atkins C.M., Kang Y., et al. Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury. J. Neurosci. Res. 2012, 90:1861-1871.
7. Atkins C.M., Cepero M.L., et al. Effects of early rolipram treatment on histopathological outcome after controlled cortical impact injury in mice. Neurosci. Lett. 2013, 532:1-6.
8. Austinat M., Braeuninger S., et al. Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke 2009, 40:285-293.
9. Ayata C., Ropper A.H. Ischaemic brain oedema. J. Clin. Neurosci. 2002, 9:113-124.
10. Bardutzky J., Schwab S. Antiedema therapy in ischemic stroke. Stroke 2007, 38:3084-3094.
11. Barone F.C., Globus M.Y., et al. Endothelin levels increase in rat focal and global ischemia. J. Cereb. Blood Flow Metab. 1994, 14:337-342.
12. Beaumont E., Whitaker C.M., et al. Effects of rolipram on adult rat oligodendrocytes and functional recovery after contusive cervical spinal cord injury. Neuroscience 2009, 163:985-990.
13. Bederson J.B., Pitts L.H., et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986, 17:472-476.
14. Bielekova B., Richert N., et al. Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 2009, 15:1206-1214.
15. Block F., Tondar A., et al. Delayed treatment with rolipram protects against neuronal damage following global ischemia in rats. Neuroreport 1997, 8:3829-3832.
16. Connolly E.S., Winfree C.J., et al. Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia. Neurosurgery 1996, 38:523-531.
17. Costa L.M., Pereira J.E., et al. Rolipram promotes functional recovery after contusive thoracic spinal cord injury in rats. Behav. Brain Res. 2013, 243:66-73.
18. Dal Piaz V., Giovannoni M.P. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. Eur. J. Med. Chem. 2000, 35:463-480.
19. de Visser Y.P., Walther F.J., et al. Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury. Eur. Respir. J. 2008, 31:633-644.
20. del Zoppo G.J., Mabuchi T. Cerebral microvessel responses to focal ischemia. J. Cereb. Blood Flow Metab. 2003, 23:879-894.
21. Dyke H.J., Montana J.G. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin. Investig. Drugs 2002, 11:1-13.
22. Enzmann G., Mysiorek C., et al. The neurovascular unit as a selective barrier to polymorphonuclear granulocyte (PMN) infiltration into the brain after ischemic injury. Acta Neuropathol. 2013, 125:395-412.
23. Folcik V.A., Smith T., et al. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. J. Neuroimmunol. 1999, 97:119-128.
24. Genain C.P., Roberts T., et al. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3601-3605.
25. Ghosh M., Garcia-Castillo D., et al. Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury. Glia 2012, 60:1839-1859.
26. Gretarsdottir S., Thorleifsson G., et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat. Genet. 2003, 35:131-138.
27. Hagedorn I., Schmidbauer S., et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010, 121:1510-1517.
28. Heydenreich N., Nolte M.W., et al. C1-inhibitor protects from brain ischemia-reperfusion injury by combined antiinflammatory and antithrombotic mechanisms. Stroke 2012, 43:2457-2467.
29. Huang Z., Mancini J.A. Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD. Curr. Med. Chem. 2006, 13:3253-3262.
30. Iadecola C., Anrather J. The immunology of stroke: from mechanisms to translation. Nat. Med. 2011, 17:796-808.
31. Jin R., Yang G., et al. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J. Leukoc. Biol. 2010, 87:779-789.
32. Jung S., Zielasek J., et al. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 1996, 68:1-11.
33. Kajana S., Goshgarian H. Systemic administration of rolipram increases medullary and spinal cAMP and activates a latent respiratory motor pathway after high cervical spinal cord injury. J. Spinal Cord Med. 2009, 32:175-182.
34. Kanes S.J., Tokarczyk J., et al. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 2007, 144:239-246.
35. Kato H., Araki T., et al. Alterations in [3H]MK-801, [3H]muscimol, [3H]cyclic AMP, and [3H]rolipram binding in the gerbil hippocampus following repeated ischemic insults. Neuroscience 1993, 52:245-253.
36. Kleinschnitz C., Stoll G. Inflammation and the role of immune mediators in the pathophysiology of ischemic stroke. Inflammation Research Perspectives 2008, 81-112. Nova Science Publishers Inc., New York. G.T. Romano (Ed.).
37. Kleinschnitz C., Stoll G., et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J. Exp. Med. 2006, 203:513-518.
38. Kleinschnitz C., Pozgajova M., et al. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007, 115:2323-2330.
39. Kleinschnitz C., Grund H., et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol. 2010, 8. (pii: e1000479).
40. Kleinschnitz C., Blecharz K., et al. Glucocorticoid insensitivity at the hypoxic blood-brain barrier can be reversed by inhibition of the proteasome. Stroke 2011, 42:1081-1089.
41. Kleinschnitz C., Kraft P., et al. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood 2013, 121:679-691.
42. Kraft P., De Meyer S.F., et al. Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'. J. Cereb. Blood Flow Metab. 2012, 32:1831-1840.
43. Krause W., Kühne G. Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences. Xenobiotica 1988, 18:561-571.
44. Kyoi T., Kitazawa S., et al. Phosphodiesterase type IV inhibitors prevent ischemia-reperfusion-induced gastric injury in rats. J. Pharmacol. Sci. 2004, 95:321-328.
45. Langhauser F., Göb E., et al. Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. Blood 2012, 120:4082-4092.
46. Li L.X., Cheng Y.F., et al. Prevention of cerebral ischemia-induced memory deficits by inhibition of phosphodiesterase-4 in rats. Metab. Brain Dis. 2011, 26:37-47.
47. Liao Y.C., Lin H.F., et al. Sex-differential genetic effect of phosphodiesterase 4D (PDE4D) on carotid atherosclerosis. BMC Med. Genet. 2010, 11:93.
48. Magnus T., Wiendl H., et al. Immune mechanisms of stroke. Curr. Opin. Neurol. 2012, 25:334-340.
49. Matsuo Y., Mihara S., et al. Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats. Stroke 2001, 32:2143-2148.
50. Mendes J.B., Rocha M.A., et al. Differential effects of rolipram on chronic subcutaneous inflammatory angiogenesis and on peritoneal adhesion in mice. Microvasc. Res. 2009, 78:265-271.
51. Moore C.S., Earl N., et al. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis. J. Pharmacol. Exp. Ther. 2006, 319:63-72.
52. Moran P.M., Higgins L.S., et al. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:5341-5345.
53. Nieswandt B., Kleinschnitz C., et al. Ischaemic stroke: a thrombo-inflammatory disease?. J. Physiol. 2011, 589:4115-4123.
54. Nikulina E., Tidwell J.L., et al. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8786-8790.
55. Okusa M.D., Linden J., et al. Enhanced protection from renal ischemia-reperfusion [correction of ischemia:reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition. Kidney Int. 2001, 59:2114-2125.
56. Pagès L., Gavaldà A., et al. PDE4 inhibitors: a review of current developments (2005-2009). Expert Opin. Ther. Pat. 2009, 19:1501-1519.
57. Pearse D., Pereira F., et al. cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nat. Med. 2004, 10:610-616.
58. Rodríguez-Palmero M., Franch A., et al. Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody. J. Rheumatol. 2006, 33:110-118.
59. Sachs B.D., Baillie G.S., et al. p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway. J. Cell Biol. 2007, 177:1119-1132.
60. Sommer N., Löschmann P.A., et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1995, 1:244-248.
61. Souness J.E., Griffin M., et al. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br. J. Pharmacol. 1996, 118:649-658.
62. Souza D.G., Cassali G.D., et al. Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury. Br. J. Pharmacol. 2001, 134:985-994.
63. Stoll G., Schroeter M., et al. Lesion-associated expression of transforming growth factor-beta-2 in the rat nervous system: evidence for down-regulating the phagocytic activity of microglia and macrophages. Brain Pathol. 2004, 14:51-58.
64. Tam F.W., Smith J., et al. Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis. Nephron 2000, 84:58-66.
65. Tsukada H., Fukumoto D., et al. Transient focal ischemia affects the cAMP second messenger system and coupled dopamine D1 and 5-HT1A receptors in the living monkey brain: a positron emission tomography study using microdialysis. J. Cereb. Blood Flow Metab. 2004, 24:898-906.
66. Wang X., Baughman K., et al. Delayed Nogo receptor therapy improves recovery from spinal cord contusion. Ann. Neurol. 2006, 60:540-549.
67. Weiss N., Miller F., et al. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim. Biophys. Acta 2009, 1788:842-857.
68. Whitaker C., Beaumont E., et al. Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury. Neurosci. Lett. 2008, 438:200-204.
69. Yang F., Liu S., et al. Tissue plasminogen activator expression and barrier properties of human brain microvascular endothelial cells. Cell. Physiol. Biochem. 2011, 28:631-638.
70. Yang F., Liu S., et al. PDE4 regulates tissue plasminogen activator expression of human brain microvascular endothelial cells. Thromb. Res. 2012, 129:750-753.
71. Yoshikawa M., Suzumura A., et al. Effects of phosphodiesterase inhibitors on cytokine production by microglia. Mult. Scler. 1999, 5:126-133.
72. Zhu J., Mix E., et al. The antidepressant and antiinflammatory effects of rolipram in the central nervous system. CNS Drug Rev. 2001, 7:387-398.